Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Insud Pharma
Deal Size : $45.0 million
Deal Type : Acquisition
Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
Details : Through the aquisition, Agile Therapeutics will combine with Insud Pharma and focus on the commercialization of Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system contraceptive.
Product Name : Twirla
Product Type : Hormone
Upfront Cash : $45.0 million
August 26, 2024
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Insud Pharma
Deal Size : $45.0 million
Deal Type : Acquisition
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Insud Pharma
Deal Size : $45.0 million
Deal Type : Merger
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Details : Through the merger, Agile Therapeutics will combine with Insud Pharma and focus on the commercialization of Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system contraceptive.
Product Name : Twirla
Product Type : Hormone
Upfront Cash : $45.0 million
June 26, 2024
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Insud Pharma
Deal Size : $45.0 million
Deal Type : Merger
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : vitaCare Prescription Services
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to expand patient access and streamline fulfillment for Twirla (levonorgestrel ethinyl estradiol) transdermal system, a once-weekly combined hormonal contraceptive (CHC) patch, indicated for use as a method of contraception by women.
Product Name : Twirla
Product Type : Hormone
Upfront Cash : Undisclosed
June 13, 2023
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : vitaCare Prescription Services
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : $7.5 million
Deal Type : Public Offering
Details : The net proceeds will be used for the Twirla (levonorgestrel and ethinyl estradiol), the first and only combined hormonal once-weekly birth control patch delivering a low dose of estrogen.
Product Name : Twirla
Product Type : Hormone
Upfront Cash : Undisclosed
March 07, 2023
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : $7.5 million
Deal Type : Public Offering
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
Details : TWIRLA is a combination of levonorgestrel, a progestin, ethinyl estradiol and estrogen. It is a hormonal contraceptives lower the risk of becoming pregnant primarily by suppressing ovulation.
Product Name : Twirla
Product Type : Hormone
Upfront Cash : Inapplicable
January 02, 2023
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Afaxys Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : This strategic agreement with Afaxys, a recognized leader in the public health system, will help ensure that Twirla is available, accessible and affordable to a much broader group of patients who can benefit from it.
Product Name : Twirla
Product Type : Hormone
Upfront Cash : Undisclosed
October 01, 2022
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Afaxys Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Twirla (levonorgestrel and ethinyl estradiol) transdermal system is combined hormonal contraceptive patch, indicated for use as a method of contraception by women of reproductive potential with a body mass index < 30 kg/m2.
Product Name : Twirla
Product Type : Hormone
Upfront Cash : Inapplicable
July 04, 2022
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Approval of Twirla (levonorgestrel) was based on SECURE study, which demonstrated safety in a large diverse group of women in a clinical trial setting.
Product Name : Twirla
Product Type : Hormone
Upfront Cash : Inapplicable
May 05, 2022
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AG200-15
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 09, 2014
Lead Product(s) : AG200-15
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levonorgestrel
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 20, 2012
Lead Product(s) : Levonorgestrel
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable